National Defense Medical Center
Taipei, 114, Taiwan
NCT Number: NCT05117970
This is a randomized controlled trial (RCT) to test a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of left ventricular systolic dysfunction.
Looking for future studies?
Notify Me20 year and older
All sexes
Interventional
Not applicable
Taipei, 114, Taiwan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative.The system will send a message to corresponding physicians if positive finding.
Time frame: Within 30 days
Ejection fraction obtained by echocardiography
Time frame: Within 30 days
After performing an electrocardiogram, the patient's survival is tracked.
Time frame: Within 30 days
After performing the ECG examination, perform the echocardiogram examination
National Defense Medical Center, Taiwan
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01918215
Cardiovascular Diseases, Heart Diseases
New Lambton, New South Wales, Australia
View Trial DetailsNCT04963686
Cardiovascular Diseases, Heart Diseases
Amiens, France
View Trial DetailsNCT07563647
Cardiovascular Diseases, Erectile Dysfunction
Kafr ash Shaykh, Kafrelsheikh Governrate, Egypt
View Trial DetailsNCT07515859
Cancer Therapy-related Cardiac Dysfunction, Cardiotoxicity
Seoul, South Korea
View Trial Details